TABLE 1.
Characteristics of 4010 Patients with myeloproliferative neoplasms, 2008–2017.
| Statin use | Pre‐matching/weighting cohort | Propensity score matching | Weighted by IPTW | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| User | Nonuser | User | Nonuser | User | Nonuser | |||||
| N (%) | N (%) | P a | %Std. diff | N (%) | N (%) | %Std. diff | (Weighted %) | (Weighted %) | %Std. diff | |
| Subtype | ||||||||||
| PV | 1011 (45.2) | 798 (45.1) | 0.95 | 0.19 | 747 (45.4) | 746 (45.3) | 0.12 | (45.3) | (45.3) | 0.11 |
| ET | 1228 (54.8) | 973 (54.9) | −0.19 | 898 (54.6) | 899 (54.7) | −0.12 | (54.7) | (54.7) | −0.11 | |
| Age at diagnosis (years) | ||||||||||
| 66–69 | 354 (15.8) | 290 (16.4) | <0.01 | −1.54 | 277 (16.8) | 265 (16.1) | 1.97 | (16.0) | (16.0) | 0.04 |
| 70–74 | 525 (23.4) | 387 (21.9) | 3.81 | 370 (22.5) | 356 (21.6) | 2.05 | (22.9) | (23.0) | −0.32 | |
| 75–79 | 519 (23.2) | 370 (20.9) | 5.52 | 352 (21.4) | 341 (20.7) | 1.64 | (21.8) | (21.6) | 0.36 | |
| 80–84 | 453 (20.2) | 340 (19.2) | 2.60 | 321 (19.5) | 325 (19.8) | −0.61 | (20.0) | (20.2) | −0.42 | |
| 85–99 | 388 (17.3) | 384 (21.7) | −11.0 | 325 (19.8) | 358 (21.8) | −4.95 | (19.4) | (19.2) | 0.36 | |
| Sex | ||||||||||
| Female | 1354 (60.5) | 1173 (66.2) | <0.01 | −12.0 | 1030 (62.6) | 1068 (64.9) | −4.81 | (62.8) | (62.3) | 1.19 |
| Male | 885 (39.5) | 598 (33.8) | 11.98 | 615 (37.4) | 577 (35.1) | 4.81 | (37.2) | (37.7) | −1.19 | |
| Race | ||||||||||
| White | 1908 (85.2) | 1573 (88.8) | <0.01 | −10.7 | 1404 (85.3) | 1452 (88.3) | −8.63 | (86.8) | (86.8) | 0.08 |
| Other | 331 (14.8) | 198 (11.2) | 10.74 | 241 (14.7) | 193 (11.7) | 8.63 | (13.2) | (13.2) | −0.08 | |
| Marital status | ||||||||||
| Married | 738 (33.0) | 565 (31.9) | 0.60 | 2.26 | 534 (32.5) | 527 (32.0) | 0.91 | (32.5) | (32.7) | −0.51 |
| Unmarried | 1327 (59.3) | 1054 (59.5) | −0.50 | 978 (59.5) | 979 (59.5) | −0.12 | (59.5) | (59.3) | 0.36 | |
| Unknown | 174 (7.8) | 152 (8.6) | −2.96 | 133 (8.1) | 139 (8.4) | −1.32 | (8.0) | (8.0) | 0.22 | |
| Hydroxyurea use | ||||||||||
| No | 550 (24.6) | 479 (27.0) | 0.07 | −5.68 | 426 (25.9) | 430 (26.1) | −0.55 | (25.6) | (25.4) | 0.48 |
| Yes | 1689 (75.4) | 1292 (73.0) | 5.68 | 1219 (74.1) | 1215 (73.9) | 0.55 | (74.4) | (74.6) | −0.48 | |
| Elixhauser comorbidity score b | ||||||||||
| 0 | 189 (8.4) | 332 (18.7) | <0.01 | −30.4 | 189 (11.5) | 216 (13.1) | −5.00 | (13.0) | (13.0) | 0.25 |
| 1 | 881 (39.3) | 750 (42.3) | −6.11 | 687 (41.8) | 740 (45.0) | −6.50 | (40.6) | (40.5) | 0.12 | |
| ≥2 | 1169 (52.2) | 689 (38.9) | 26.96 | 769 (46.7) | 689 (41.9) | 9.80 | (46.4) | (46.5) | −0.29 | |
| History of thrombosis | ||||||||||
| No | 1718 (76.7) | 1536 (86.7) | <0.01 | −26.1 | 1329 (80.8) | 1410 (85.7) | −13.2 | (81.1) | (80.8) | 0.60 |
| Yes | 521 (23.3) | 235 (13.3) | 26.10 | 316 (19.2) | 235 (14.3) | 13.22 | (18.9) | (19.2) | −0.60 | |
| Disability status | ||||||||||
| No | 1985 (88.7) | 1573 (88.8) | 0.87 | −0.52 | 1455 (88.4) | 1461 (88.8) | −1.15 | (88.8) | (88.9) | −0.14 |
| Yes | 254 (11.3) | 198 (11.2) | 0.52 | 190 (11.6) | 184 (11.2) | 1.15 | (11.2) | (11.1) | 0.14 | |
| State buy‐in | ||||||||||
| No | 1823 (81.4) | 1467 (82.8) | 0.25 | −3.69 | 1342 (81.6) | 1362 (82.8) | −3.18 | (82.2) | (82.1) | 0.34 |
| Yes | 416 (18.6) | 304 (17.2) | 3.69 | 303 (18.4) | 283 (17.2) | 3.18 | (17.8) | (17.9) | −0.34 | |
| Yost index | ||||||||||
| Fifth quintile (highest SES) | 708 (31.6) | 586 (33.1) | 0.23 | −3.14 | 473 (28.8) | 534 (32.5) | −8.05 | (32.2) | (32.2) | 0.04 |
| Fourth quintile | 445 (19.9) | 382 (21.6) | −4.18 | 376 (22.9) | 355 (21.6) | 3.07 | (20.8) | (21.0) | −0.35 | |
| Third quintile | 402 (18.0) | 281 (15.9) | 5.57 | 291 (17.7) | 266 (16.2) | 4.05 | (17.0) | (16.8) | 0.56 | |
| Second quintile | 354 (15.8) | 288 (16.3) | −1.23 | 275 (16.7) | 263 (16.0) | 1.97 | (16.1) | (16.1) | −0.11 | |
| First quintile (lowest SES) | 244 (10.9) | 175 (9.9) | 3.33 | 174 (10.6) | 168 (10.2) | 1.20 | (10.4) | (10.4) | −0.03 | |
| Unknown | 86 (3.8) | 59 (3.3) | 2.74 | 56 (3.4) | 59 (3.6) | −0.99 | (3.5) | (3.6) | −0.22 | |
| Receipt of influenza vaccination in the 12 months before PV or ET diagnosis | ||||||||||
| No | 760 (33.9) | 712 (40.2) | <0.01 | −13.0 | 625 (38.0) | 635 (38.6) | −1.25 | (36.9) | (36.8) | 0.23 |
| Yes | 1479 (66.1) | 1059 (59.8) | 12.99 | 1020 (62.0) | 1010 (61.4) | 1.25 | (63.1) | (63.2) | −0.23 | |
Abbreviations: CI, confidence interval; ET, essential thrombocythemia; IPTW, inverse probability of treatment weighting; PV, polycythemia vera; Std. diff, standardized difference.
a
p‐Values were derived from chi‐squared tests for categorical variables and t‐tests for continuous variables.
b
Prior thrombotic events were not included in the modified Elixhauser score.